title: Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b.
abstract: OBJECTIVE
  The aim of this study was to clarify which or how factors could influence the probability of sustained virological response (SVR) in 24-week telaprevir-based triple combination therapy for East Asian chronic hepatitis C patients infected with hepatitis C virus genotype 1b.
  
  
  METHODS
  Of 140 patients who were enrolled in this study, 137 received 12-week telaprevir combined with 24-week pegylated interferon alpha-2b plus ribavirin and were subjected to the analysis. Factors associated with SVR were analyzed by multiple logistic regression analysis.
  
  
  RESULTS
  Of the 137 patients, 112 (82%) achieved SVR. Of 87 patients with IL28B single nucleotide polymorphism rs8099917 genotype TT, 84 (97%) achieved SVR. By contrast, 28 of 50 (56%) patients with the genotype TG/GG had SVR (P = 3.29 × 10(-9) ). Fifty-three of 60 (88%) naïve patients and 50 of 54 (93%) prior relapsers achieved SVR. Nine of 13 (69%) prior partial responders and none of 10 (0%) prior null responders achieved SVR. Multivariable analysis identified four independent factors that were significantly associated with SVR: IL28B SNP rs8099917 genotype (P = 6.90 × 10(-5) ), pre-existence of cirrhosis (P = 3.99 × 10(-3) ), prior treatment response (P = 0.0126), and rapid virological response (P = 0.0239).
  
  
  CONCLUSIONS
  The IL28B single nucleotide polymorphism still remained informative as a predictor of SVR to 24-week telaprevir-based triple combination therapy for East Asian patients infected with hepatitis C virus genotype 1b.
authors.affiliation: Institute of Clinical Medicine and Research (ICMR), Jikei University School of Medicine, Kashiwa, Chiba, Japan; Division of Gastroenterology and Hepatology, Kashiwa Hospital, Jikei University School of Medicine, Kashiwa, Chiba, Japan.
authors.forename: Akihito
authors.initials: A
authors.lastname: Tsubota
authors.forename: Noritomo
authors.initials: N
authors.lastname: Shimada
authors.forename: Masanori
authors.initials: M
authors.lastname: Atsukawa
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Abe
authors.forename: Keizo
authors.initials: K
authors.lastname: Kato
authors.forename: Makiko
authors.initials: M
authors.lastname: Ika
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Matsudaira
authors.forename: Keisuke
authors.initials: K
authors.lastname: Nagatsuma
authors.forename: Tomokazu
authors.initials: T
authors.lastname: Matsuura
authors.forename: Yoshio
authors.initials: Y
authors.lastname: Aizawa
mesh_terms: D000328:Adult; D000368:Aged; D000998:Antiviral Agents / Q000008:administration & dosage*; D044466:Asian People; D004359:Drug Therapy, Combination; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics*; D019698:Hepatitis C, Chronic / Q000188:drug therapy / Q000235:genetics* / Q000821:virology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D007372:Interferons; D007378:Interleukins / Q000235:genetics*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D009842:Oligopeptides / Q000008:administration & dosage*; D010597:Pharmacogenetics; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D020641:Polymorphism, Single Nucleotide / Q000235:genetics*; D057285:Precision Medicine; D011994:Recombinant Proteins / Q000008:administration & dosage; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult; D000095022:Interferon Lambda
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007372:Interferons; D007378:Interleukins; D009842:Oligopeptides; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; C000624353:interferon-lambda, human; D000095022:Interferon Lambda; C486464:telaprevir; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a
keywords: IL28B single nucleotide polymorphism; chronic hepatitis C virus infection; pegylated interferon; ribavirin; sustained virological response; telaprevir